Evotec SE: Translational BRIDGE beLAB2122 in collaboration with Bristol Myers Squibb identifies the first project
- FIRST PROJECT ORIGIN OF THE GERMAN CANCER RESEARCH CENTER (“DKFZ”) AND THE UNIVERSITY OF HEIDELBERG IN HEIDELBERG
- beLAB2122 IS A BRIDGE TRANSLATION COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB
Hamburg, Germany, October 27, 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX / TecDAX, ISIN: DE0005664809) today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions in the Rhine-Main-Neckar region of Germany with the aim of effectively advancing first-class treatment options in all therapeutic fields and formats in drug discovery and early development projects that can be invested. After the signing of the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic collaboration BRIDGE is now nominated.
Coming from the laboratory of Dr Darjus Tschaharganeh, group leader at the German Cancer Research Center (“DKFZ”), Heidelberg, and professor at the University of Heidelberg, the project is based on the observation of synthetic lethal interactions in certain types of cancer and is aimed at the development of small molecules that inhibit a transporter of nutrients essential for the survival of these cancer cells.
beLAB2122 will now rely on Evotec’s integrated discovery and development platform to validate and further develop the project. The objective of beLAB2122 is to develop academic projects to enhance the inflection points that allow the formation of new spin-off companies held jointly.
Dr Thomas Hanke, Executive Vice President and Head of Academic Partnerships at Evotec, commented: “We are delighted to further explore the promising approach of DKFZ and Heidelberg University as the first funded project of beLAB2122. Evotec’s BRIDGE collaborations aim to seamlessly integrate academic innovations into the pharmaceutical value chain and accelerate them towards new business training. We look forward to advancing this and many other interesting academic projects using Evotec’s highly efficient integrated drug discovery and development infrastructure, known as the “Data-Driven R&D Highway to Cures”. At the same time, we are delighted to receive further promising applications from scientists working within the beLAB2122 member institutions of EMBL, the German Cancer Research Center, Goethe University Frankfurt, Heidelberg University and the University of Tübingen, and look forward to further expanding the scope of the project portfolio. ”
Dr Darjus Tschaharganeh, group leader at the German Cancer Research Center (DKFZ) and professor at the University of Heidelberg, added: “We are delighted to be chosen as the first beLAB2122 project and to be part of the collaboration bridge. Our project arose out of basic fundamental research and we are now at a point where our results clearly illustrate that pharmacological inhibitors for this target could be very effective. for the treatment of cancer. The beLAB2122 initiative with strong pharmaceutical partners is ideal to continue this project. We look forward to close interaction with Evotec and Bristol Myers Squibb and hope that we can find potent inhibitors for our target in order to reach the next step and hopefully will be able to bring this in the future to clinics for the benefit of patients. ”
beLAB2122 is supported by Evotec in collaboration with Bristol Myers Squibb. The total volume of US $ 20 million will allow several additional funding rounds. For more information on beLAB2122, visit www.belab2122.org.
About Evotec’s BRIDGE model: partnering to accelerate innovation
Evotec has created a new paradigm for translating early-stage academic research into drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated fund and reward framework to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotechnology. Through these efforts, Evotec has defined a new formula to accelerate early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has trained and funded a number of different collaborations, for example LAB282, LAB150, LAB031, LAB10x, Autobahn Labs, Argobio and Danube-Labs. Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec BRIDGEs.
This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “could”, “could”, “could”, “,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding the completion of the offer. These forward-looking statements are based on available information and expectations and assumptions believed to be reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. ent any obligation or commitment to publicly publish any update or revision to any forward-looking statement contained herein to reflect any change in Evotec’s expectations in this regard or any change in the events, conditions or circumstances on which a statement is based.
Evotec SE published this content on October 27, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on October 27, 2021 09:27:06 AM UTC.